Shield Therapeutics announces results from it’s Pre-Submission meeting with the FDA and confirms plans to submit a New Drug Application for Feraccru. This press release provides a strategic review update and announces the appointment of a Non-Executive Director. For further details please see the press release attached.
Webcast and conference call for analysts at 1pm BST today
Carl Sterritt, Chief Executive Officer, Dr Karl Keegan, Chief Financial Officer and Dr Mark Sampson, Chief Medical Officer, will host a live conference call and webcast for analysts at 1pm BST today, 6 April 2018, to discuss this announcement.
Dial in details:
|United Kingdom||Participant||+44 (0)330 336 9105|
|United States||Participant||+1 646-828-8156|
The participation code is: 8668739Back to news